The purpose of this registry is to evaluate the safety and efficacy of RIC for patients with symptomatic intracranial atherosclerotic stenosis (sICAS) undergoing endovascular therapy.
Patient admitted from Jan. 1st 2023 to Jan. 1st 2025;
Age ≥ 18;
Intracranial atherosclerosis stenosis measured as ≥70% by digital subtraction angiography or by other noninvasive methods, such as transcranial doppler, computed tomography angiography, or magnetic resonance angiography;
A history of stroke/transient ischemic attack attributed to ICAS;
Stenosis of other causes;
Prior ipsilateral stroke with residual deficits;
Uncontrolled hypertension (defined as systolic blood pressure ≥200 mm Hg despite medications at enrollment);
Peripheral vascular disease (especially subclavian arterial and upper limb artery stenosis or occlusion).